Daewoong Pharmaceuticals

daewoong.com

Establish in 1945, Daewoong Pharmaceuticals Co., Ltd. is a public South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both the domestic and international markets. Through our strong M&S divisions, Daewoong has the largest prescription drug sales in the South Korean market. Presently, we commercialize 10 blockbuster products. In addition, we have built a strong internal core competency for new drug development and have expanded regional and global collaborations with international partners. To reach our goal to become a global health care company, Daewoong has expanded international operations establishing branches offices throughout Asia and research centers in the US, China, and India. Currently, Daewoong is constructing a new manufacturing facility under cGMP guidelines to meet the needs of our global partners.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

ORBIT DISCOVERY AND WUXI APPTEC SIGN AGREEMENT TO ACCESS PEPTIDE DISCOVERY AND OPTIMISATION TECHNOLOGIES

Orbit Discovery | March 08, 2022

news image

Orbit Discovery a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide p...

Read More

BUSINESS INSIGHTS

CELLUSION AND CELREGEN A MEMBER OF FOSUN PHARMA, ENTER INTO EXCLUSIVE LICENSE AGREEMENT OF CLS001 FOR A CORNEAL ENDOTHELIAL CELL REGENERATIVE

Cellusion and Celregen | September 12, 2022

news image

Cellusion Inc. a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells for bullous keratopathy novel treatment and Hangzhou Celregen Therapeutics Ltd. a member of Shanghai Fosun Pharmaceutical Co., Ltd. and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital announced an exclusive...

Read More

PHARMA TECH

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

news image

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More

BUSINESS INSIGHTS

INTEGRICHAIN PARTNERS WITH PURPLELAB TO ENHANCE PHARMACEUTICAL CHANNEL DATA FOR MORE ACCURATE GTN FORECASTING AND ACCRUALS

IntegriChain | November 18, 2022

news image

IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, announced a strategic data partnership with PurpleLab, a healthcare technology company delivering analytics to drive real-world evidence decision-making. As a first step to this partnership, IntegriChain will incorporate PurpleLab prescription drug claims data to address challenges in visibility to demand and inventory that has resulted from evolving ...

Read More
news image

PHARMACY MARKET

ORBIT DISCOVERY AND WUXI APPTEC SIGN AGREEMENT TO ACCESS PEPTIDE DISCOVERY AND OPTIMISATION TECHNOLOGIES

Orbit Discovery | March 08, 2022

Orbit Discovery a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide p...

Read More
news image

BUSINESS INSIGHTS

CELLUSION AND CELREGEN A MEMBER OF FOSUN PHARMA, ENTER INTO EXCLUSIVE LICENSE AGREEMENT OF CLS001 FOR A CORNEAL ENDOTHELIAL CELL REGENERATIVE

Cellusion and Celregen | September 12, 2022

Cellusion Inc. a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells for bullous keratopathy novel treatment and Hangzhou Celregen Therapeutics Ltd. a member of Shanghai Fosun Pharmaceutical Co., Ltd. and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital announced an exclusive...

Read More
news image

PHARMA TECH

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More
news image

BUSINESS INSIGHTS

INTEGRICHAIN PARTNERS WITH PURPLELAB TO ENHANCE PHARMACEUTICAL CHANNEL DATA FOR MORE ACCURATE GTN FORECASTING AND ACCRUALS

IntegriChain | November 18, 2022

IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, announced a strategic data partnership with PurpleLab, a healthcare technology company delivering analytics to drive real-world evidence decision-making. As a first step to this partnership, IntegriChain will incorporate PurpleLab prescription drug claims data to address challenges in visibility to demand and inventory that has resulted from evolving ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us